Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Other Non Operating Income (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Other Non Operating Income for 7 consecutive years, with $247000.0 as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income rose 112.65% to $247000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $215000.0 through Dec 2025, up 105.48% year-over-year, with the annual reading at $215000.0 for FY2025, 105.48% up from the prior year.
  • Other Non Operating Income hit $247000.0 in Q4 2025 for Allogene Therapeutics, up from -$81000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $2.1 million in Q1 2023 to a low of -$6.9 million in Q4 2023.
  • Historically, Other Non Operating Income has averaged -$1.4 million across 5 years, with a median of -$919000.0 in 2021.
  • Biggest five-year swings in Other Non Operating Income: plummeted 651.22% in 2022 and later surged 125.03% in 2023.
  • Year by year, Other Non Operating Income stood at -$1.8 million in 2021, then tumbled by 101.27% to -$3.6 million in 2022, then plummeted by 90.65% to -$6.9 million in 2023, then skyrocketed by 71.85% to -$2.0 million in 2024, then skyrocketed by 112.65% to $247000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for ALLO at $247000.0 in Q4 2025, -$81000.0 in Q3 2025, and -$43000.0 in Q2 2025.